LY3295668
CAS No. 1919888-06-4
LY3295668( LY-329566 | LY 329566 | AK-01 )
Catalog No. M13011 CAS No. 1919888-06-4
LY3295668 (LY-3295668, AK-01) is a novel potent, highly selective, orally active Aurora-A kinase inhibitor with Ki of 0.8 nM, H446 AurA auto-P IC50 of 0.6 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 320 | In Stock |
|
| 10MG | 475 | In Stock |
|
| 25MG | 770 | In Stock |
|
| 50MG | 1062 | In Stock |
|
| 100MG | 1431 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY3295668
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY3295668 (LY-3295668, AK-01) is a novel potent, highly selective, orally active Aurora-A kinase inhibitor with Ki of 0.8 nM, H446 AurA auto-P IC50 of 0.6 nM.
-
DescriptionLY3295668 (LY-3295668, AK-01) is a novel potent, highly selective, orally active Aurora-A kinase inhibitor with Ki of 0.8 nM, H446 AurA auto-P IC50 of 0.6 nM; displays >1000-fold selectivity over Aur-B, 5/386 kinases were potently inhibited by LY3295668 (<10 nM) and none of these kinases overlapped with targets of the other AurAi (MK5108, alisertib), and no inhibition of SYK; LY3295668 is cytotoxic to RB1 mutant cancer cancaer cells (NCI-H446 cell IC50=0.752 uM), causes durable regression of RB1mut tumor xenografts.Solid Tumors Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsLY-329566 | LY 329566 | AK-01
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAurora Kinase
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1919888-06-4
-
Formula Weight489.952
-
Molecular FormulaC24H26ClF2N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 150 mg/mL 306.15 mM
-
SMILESClC1=CC=CC(CN2CC[C@](C(O)=O)(CC3=C(F)C=CC(NC4=NNC(C)=C4)=N3)C[C@H]2C)=C1F
-
Chemical Name(2R,4R)-1-(3-chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gong X, et al. Cancer Discov. 2018 Oct 29. pii: CD-18-0469.
molnova catalog
related products
-
CYC-116
A potent and selective Aurora A/Aurora B inhibitor with IC50 of 8.0/9.2 nM; shows >50-fold selectivity over CDK1/2/4/7/9.
-
GSK-1070916
A potent, selective and ATP-competitive inhibitor of Aurora B and C with Ki of 0.38 nM and 1.5 nM, respectively.
-
CCT 137690
A potent, orally bioavailable Aurora kinases inhibitor with IC50 of 15/25/19 nM for Aurora A/B/C; displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI50=0.30 uM) and A2780 ovarian cancer cell line (GI50=0.14 uM).
Cart
sales@molnova.com